161 related articles for article (PubMed ID: 21734015)
1. Dual function of ERRα in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin.
Fradet A; Sorel H; Bouazza L; Goehrig D; Dépalle B; Bellahcène A; Castronovo V; Follet H; Descotes F; Aubin JE; Clézardin P; Bonnelye E
Cancer Res; 2011 Sep; 71(17):5728-38. PubMed ID: 21734015
[TBL] [Abstract][Full Text] [Related]
2. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
Fisher JL; Thomas-Mudge RJ; Elliott J; Hards DK; Sims NA; Slavin J; Martin TJ; Gillespie MT
Cancer Res; 2006 Apr; 66(7):3620-8. PubMed ID: 16585187
[TBL] [Abstract][Full Text] [Related]
3. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases.
van der Pluijm G; Sijmons B; Vloedgraven H; Deckers M; Papapoulos S; Löwik C
J Bone Miner Res; 2001 Jun; 16(6):1077-91. PubMed ID: 11393785
[TBL] [Abstract][Full Text] [Related]
4. PTHrP regulates angiogenesis and bone resorption via VEGF expression.
Isowa S; Shimo T; Ibaragi S; Kurio N; Okui T; Matsubara K; Hassan NM; Kishimoto K; Sasaki A
Anticancer Res; 2010 Jul; 30(7):2755-67. PubMed ID: 20683010
[TBL] [Abstract][Full Text] [Related]
5. cAMP-response-element-binding protein positively regulates breast cancer metastasis and subsequent bone destruction.
Son J; Lee JH; Kim HN; Ha H; Lee ZH
Biochem Biophys Res Commun; 2010 Jul; 398(2):309-14. PubMed ID: 20599715
[TBL] [Abstract][Full Text] [Related]
6. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.
Morony S; Capparelli C; Sarosi I; Lacey DL; Dunstan CR; Kostenuik PJ
Cancer Res; 2001 Jun; 61(11):4432-6. PubMed ID: 11389072
[TBL] [Abstract][Full Text] [Related]
7. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
Buijs JT; Henriquez NV; van Overveld PG; van der Horst G; Que I; Schwaninger R; Rentsch C; Ten Dijke P; Cleton-Jansen AM; Driouch K; Lidereau R; Bachelier R; Vukicevic S; Clézardin P; Papapoulos SE; Cecchini MG; Löwik CW; van der Pluijm G
Cancer Res; 2007 Sep; 67(18):8742-51. PubMed ID: 17875715
[TBL] [Abstract][Full Text] [Related]
8. Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147.
Rucci N; Millimaggi D; Mari M; Del Fattore A; Bologna M; Teti A; Angelucci A; Dolo V
Cancer Res; 2010 Aug; 70(15):6150-60. PubMed ID: 20631064
[TBL] [Abstract][Full Text] [Related]
9. The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis.
Yee AJ; Akens M; Yang BL; Finkelstein J; Zheng PS; Deng Z; Yang B
Breast Cancer Res; 2007; 9(4):R47. PubMed ID: 17662123
[TBL] [Abstract][Full Text] [Related]
10. Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer.
Ariazi EA; Clark GM; Mertz JE
Cancer Res; 2002 Nov; 62(22):6510-8. PubMed ID: 12438245
[TBL] [Abstract][Full Text] [Related]
11. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway.
Katsuno Y; Hanyu A; Kanda H; Ishikawa Y; Akiyama F; Iwase T; Ogata E; Ehata S; Miyazono K; Imamura T
Oncogene; 2008 Oct; 27(49):6322-33. PubMed ID: 18663362
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo.
Garvin S; Dabrosin C
Cancer Res; 2003 Dec; 63(24):8742-8. PubMed ID: 14695189
[TBL] [Abstract][Full Text] [Related]
13. Osteoactivin promotes breast cancer metastasis to bone.
Rose AA; Pepin F; Russo C; Abou Khalil JE; Hallett M; Siegel PM
Mol Cancer Res; 2007 Oct; 5(10):1001-14. PubMed ID: 17951401
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.
Hiraga T; Kizaka-Kondoh S; Hirota K; Hiraoka M; Yoneda T
Cancer Res; 2007 May; 67(9):4157-63. PubMed ID: 17483326
[TBL] [Abstract][Full Text] [Related]
15. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast.
Brown LF; Guidi AJ; Schnitt SJ; Van De Water L; Iruela-Arispe ML; Yeo TK; Tognazzi K; Dvorak HF
Clin Cancer Res; 1999 May; 5(5):1041-56. PubMed ID: 10353737
[TBL] [Abstract][Full Text] [Related]
16. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
17. Control of VEGF expression in triple-negative breast carcinoma cells by suppression of SAF-1 transcription factor activity.
Ray A; Dhar S; Ray BK
Mol Cancer Res; 2011 Aug; 9(8):1030-41. PubMed ID: 21665940
[TBL] [Abstract][Full Text] [Related]
18. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.
Yonou H; Kanomata N; Goya M; Kamijo T; Yokose T; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
Cancer Res; 2003 May; 63(9):2096-102. PubMed ID: 12727825
[TBL] [Abstract][Full Text] [Related]
20. [Inhibitive effects of mifepristone on growth of breast cancer: experiment with animal model].
Tian XS; Zhou WH; Wu GJ; Sun JZ; Cong MH
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(8):559-63. PubMed ID: 18649774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
